Fractyl Health, Inc. (GUTS) is a clinical-stage metabolic therapeutics company, not an exchange-traded fund, so this analysis is built around equity analyst price targets rather than fund metrics. The target picture is complicated by a 1-for-12 reverse stock split effective in early October 2026, which reset the share count and price scale while some older forecasts lagged behind.
Among recently updated, reverse-split-adjusted targets, the range spans roughly $2 to $8. Morgan Stanley maintained a Hold rating with a $4 target in October 2026, Craig-Hallum maintained Buy with a $5 target, and H.C. Wainwright maintained Buy with an $8 target. Independent aggregators such as TipRanks and MarketBeat report a current average analyst price target near $5, with a low of $2 and a high of $8. Because a few aggregators still display pre-split figures as high as $72 (and intermediate values like $24), a naive consensus can appear far higher; the $5 figure used here reflects the average of the updated, post-split estimates rather than those stale entries.
The stock traded near $0.81 in early November 2026, giving the company a market capitalization of only about $11 million. Reaching the $5 central target would require an increase of roughly 500%, an exceptionally large move that is typical only of binary, data-driven biotech outcomes. The path to such a level would almost certainly depend on clinical and regulatory milestones rather than gradual fundamental progress, because the company currently records no product revenue and a trailing net loss of roughly $106 million.
Fractyl's lead asset is Revita, an endoscopic procedure intended to help patients maintain weight loss after discontinuing GLP-1 therapies. In October 2026 the company reported positive six-month REMAIN-1 pivotal data showing Revita participants maintained about 80% of their GLP-1-induced weight loss versus 67% for sham (p=0.0023), a result that supports the durability thesis central to the bullish analyst targets. Management also announced a restructuring to concentrate resources on Revita, and insiders, including the CEO and directors, made open-market purchases in mid-2026, a modest signal of internal conviction. A large addressable market around post-GLP-1 weight maintenance underpins the highest price forecasts.
The risks are substantial. Fractyl has no commercial revenue, roughly $61 million in debt against about $47 million in cash, and a negative book value, meaning the $5 target depends on future financing and successful clinical execution rather than current fundamentals. The company has already used a reverse split to address Nasdaq's minimum-price listing rules, and further dilution remains a live concern for a pre-revenue biotech. A restructuring announced in October 2026 also signals financial pressure, and the wide analyst range reflects genuine disagreement about whether Revita can become a commercially meaningful product.
The stock has fallen roughly 94% over the past year, and its 50-day and 200-day moving averages sit well above the current price, indicating a deeply impaired long-term trend. The post-split 52-week range stretches from about $0.82 to $29.34, but the upper portion reflects pre-split pricing distortions. In practical terms, any sustained move toward $5 would first need to reclaim and hold levels far above the current price, with no meaningful nearby support zone beyond the recent lows.
Analyst price targets generally reflect a 12-month research horizon, though for a distressed biotech the effective horizon is often tied to discrete catalysts rather than a calendar. The next earnings report is scheduled for November 12, 2026. Investors should monitor follow-up REMAIN-1 and REVEAL-1 data, cash runway and any financing announcements, Nasdaq listing compliance, restructuring updates, and further analyst target revisions as the reverse-split-adjusted forecasts settle.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a high-volatility name like Fractyl Health, such tools can help traders track shifts in momentum and structure more efficiently than manual screening alone. Traders interested in a systematic approach can use these signals to discover opportunities, monitor positions, and spot changing trends in real time.
The question of whether Fractyl Health can reach $5 hinges on a clinical and financing story rather than a valuation story. The $5 central target, derived from the updated post-reverse-split analyst range of roughly $2 to $8, sits about 500% above the current price, a very large required move. Support rests on positive REMAIN-1 data and a narrowed focus on Revita, while the principal obstacles are negative equity, ongoing cash burn, delisting risk, and the possibility of further dilution. With analyst views spanning Hold at $4 to Buy at $8 and older unadjusted figures still distorting some consensus tools, investors should weigh the binary clinical outcome against the company's strained balance sheet, and monitor upcoming earnings and financing developments closely.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, GUTS has been loosely correlated with REVB. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if GUTS jumps, then REVB could also see price increases.
| Ticker / NAME | Correlation To GUTS | 1D Price Change % | ||
|---|---|---|---|---|
| GUTS | 100% | -9.63% | ||
| REVB - GUTS | 37% Loosely correlated | -3.07% | ||
| MNKD - GUTS | 31% Poorly correlated | +0.95% | ||
| SPRB - GUTS | 29% Poorly correlated | -5.42% | ||
| RXRX - GUTS | 29% Poorly correlated | -6.70% | ||
| HIND - GUTS | 28% Poorly correlated | -3.14% | ||
More | ||||